Journal ArticleDOI
Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials.
TLDR
It is suggested that although blonanserin has a more beneficial effect on negative symptoms than haloperidol, there was a significant difference in the adverse events profile between blonANSerin and other antipsychotics.About:
This article is published in Journal of Psychiatric Research.The article was published on 2013-02-01. It has received 53 citations till now. The article focuses on the topics: Blonanserin.read more
Citations
More filters
Journal ArticleDOI
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
Yu Zhou,Jiang Wang,Zhanni Gu,Shuni Wang,Wei Zhu,José Luis Aceña,Vadim A. Soloshonok,Kunisuke Izawa,Hong Liu +8 more
TL;DR: Compounds Currently in Phase II−III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas is presented.
Journal ArticleDOI
Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
TL;DR: This study aimed to perform a comprehensive meta‐analysis of minocycline augmentation therapy in patients with schizophrenia receiving antipsychotic agents.
Journal ArticleDOI
Profile of blonanserin for the treatment of schizophrenia
Tomomi Tenjin,Seiya Miyamoto,Yuriko Ninomiya,Rei Kitajima,Shin Ogino,Nobumi Miyake,Noboru Yamaguchi +6 more
TL;DR: Results suggest that blonanserin may be a promising candidate for a first-line antipsychotic for acute and maintenance therapy for schizophrenia.
Journal ArticleDOI
Improving Current Treatments for Schizophrenia
TL;DR: A review of the current status of drugs under investigation can be found in this article, where the authors emphasize that the development of the novel compounds to target the underlying cognitive dysfunction and negative symptom dimension of full-blown schizophrenia, or attenuated psychosis syndrome and specific endophenotypes related to the increased risk of psychosis in the general population, alongside efforts to deconstruct the concept of schizophrenia(s), represent the best way to meet patient needs for better therapies and more favorable outcomes.
Journal ArticleDOI
A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia
TL;DR: Well-designed clinical trials, mainly direct “head-to-head” comparisons with other second-generation antipsychotic agents, are needed to define the therapeutic role and safety profile of cariprazine in schizophrenia and bipolar mania.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Meta-Analysis in Clinical Trials*
TL;DR: This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
Journal ArticleDOI
The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia
TL;DR: Review of five studies involving the PANSS provided evidence of its criterion-related validity with antecedent, genealogical, and concurrent measures, its predictive validity, its drug sensitivity, and its utility for both typological and dimensional assessment.
Journal ArticleDOI
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Stefan Leucht,Caroline Corves,Caroline Corves,Dieter Arbter,Rolf R. Engel,Chunbo Li,Chunbo Li,John M. Davis +7 more
TL;DR: A meta-analysis of randomised controlled trials to compare the effects of second-generation antipsychotic drugs in patients with schizophrenia provided data for individualised treatment based on efficacy, side-effects, and cost.
Journal ArticleDOI
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
TL;DR: A brief review and critique of the current therapeutic armamentarium for treating schizophrenia and drug development strategies and theories of mechanisms of action of antipsychotic drugs is provided, and focuses on novel targets for therapeutic agents for future drug development.
Related Papers (5)
Blonanserin: a review of its use in the management of schizophrenia.
Emma D. Deeks,Gillian M. Keating +1 more